Female Carriers and Cardiomyopathy in Duchenne Muscular Dystrophy

Female carriers of Duchenne muscular dystrophy are women who carry a pathogenic variant in one copy of the dystrophin gene. The textbook picture is that they are asymptomatic and pass the mutation to their sons. The clinical reality is more complicated: a meaningful proportion of carriers develop mild muscle symptoms, and a sizeable subset develop cardiomyopathy, sometimes as the only clinical manifestation of the gene variant. This makes routine cardiac surveillance for carriers part of standard care, not an optional extra.

This post is a practical overview. The actual surveillance and treatment plan belongs to the carrier and her care team.

Why carriers are not always asymptomatic

DMD is X-linked. Females usually have two X chromosomes and produce dystrophin from the unaffected copy. The protective effect of having a second X is real, but it is not absolute. Random X-chromosome inactivation, sometimes called lyonisation, can leave a carrier with a higher-than-expected proportion of cells expressing the affected X. The result is a clinical spectrum that runs from no symptoms at all to occasional mild skeletal muscle weakness to, less commonly, more substantial weakness that resembles a milder DMD or Becker phenotype. (A manifesting female carrier of DMD, PMC)

The term “manifesting carrier” is used in the literature for women whose carrier status produces noticeable clinical features. The proportion of carriers who fit this label is small but not negligible.

The cardiac dimension is more important than the muscle dimension

The clinical story that has changed most over the last two decades is cardiac. Studies have documented that cardiac involvement is far more common in carriers than skeletal muscle involvement, and that it often appears without any muscle complaints. (Detection and management of cardiomyopathy in female dystrophinopathy carriers, ScienceDirect)

Reported numbers vary by population and screening method, but several patterns appear repeatedly:

• Echocardiographic abnormalities have been documented in a wide proportion of carriers, with reports across the literature ranging from a small minority to a majority depending on age and method.
• Dilated cardiomyopathy has been estimated to occur in roughly 7 to 16 percent of female DMD carriers. (Cardiac involvement in women with pathogenic dystrophin variants, Frontiers in Neurology)
• Cardiomyopathy may be the only clinical manifestation of the dystrophin gene mutation in some carriers, with no skeletal muscle symptoms at all.
• The inferolateral wall of the left ventricle is the area most commonly affected, mirroring the pattern seen in DMD itself.

The clinical implication is straightforward: a carrier without muscle symptoms is not automatically without cardiac risk.

What surveillance looks like

Most published recommendations support routine cardiac surveillance for known DMD carriers. Specific approaches vary by centre and country, but a common pattern is:

• Initial cardiology referral when carrier status is confirmed.
• Baseline electrocardiogram and echocardiogram.
• Cardiac MRI in selected cases, particularly when imaging by echo is suboptimal or when there is reason to look for early fibrosis. For background, see cardiac MRI in DMD.
• Repeat imaging at intervals matched to the patient’s age, prior findings, and symptoms. Many programmes use intervals of several years for asymptomatic carriers with normal baseline studies, with shorter intervals when abnormalities appear.
• Earlier and more frequent assessment when carriers are pregnant or planning pregnancy, since pregnancy stresses the cardiovascular system.

When cardiomyopathy is identified, treatment generally follows standard heart-failure principles, including ACE inhibitors, beta blockers, and other heart-failure therapies as indicated. The threshold for starting medications can be lower than in the general population, because the natural history of dystrophinopathy-associated cardiomyopathy can be progressive.

For background, see cardiac care in DMD.

When to test

Most carriers are identified through family genetic counselling after a son is diagnosed with DMD. For background, see genetic counseling for Duchenne families and DMD carrier mothers.

Carrier testing is typically offered to:

• Mothers, sisters, and adult daughters of patients with DMD.
• Female relatives identified through pedigree analysis.
• Women with unexplained dilated cardiomyopathy and a relevant family history, even when the family history is partial.

A woman who learns she is a carrier as part of family testing should be offered cardiac surveillance, not just genetic counselling. Studies of mothers of DMD patients have found unrecognised heart disease at higher rates than in the general population, and the data continues to expand. (Heart Disease in Mothers of Children with DMD, PMC)

What is often missed

A few practical realities in current clinical practice:

• Carriers identified through paediatric genetic counselling are not always handed off to adult cardiology in a structured way.
• Carriers who never sought confirmation (because they had no symptoms) may not appear in the registry of patients who need surveillance.
• Cardiomyopathy can be subclinical for years before producing symptoms, particularly when activity levels are modest.

A planned referral pathway and a written carrier-specific surveillance schedule, similar to what exists for affected sons, addresses most of these gaps.

For broader family context, see DMD carrier mothers.

What carriers can ask

A short list at clinic visits:

• Has a baseline echocardiogram been done, and when is the next imaging due?
• Should cardiac MRI be part of the assessment, particularly in the inferolateral wall?
• What is the plan during and after pregnancy if relevant?
• Are there cardiac symptoms (palpitations, breathlessness, reduced exercise tolerance) that should prompt earlier assessment?
• Who in the local cardiology service has experience with dystrophinopathy carriers?

These questions move carriers from a forgotten category to a tracked patient population.

What is still uncertain

Optimal surveillance intervals for asymptomatic carriers, the role of newer cardiac imaging and biomarkers, the contribution of specific genetic variants to risk, and the integration of carrier surveillance into adult cardiology continue to evolve.

The reasonable framing is that carrier surveillance is part of family-level DMD care, not a separate concern. The decisions belong to the carrier and an adult cardiologist with neuromuscular experience.

For related reading, see DMD carrier mothers, genetic counseling for Duchenne families, cardiac care in DMD, cardiac MRI in DMD, and the reported piece Two Mothers, Two Realities.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.